Medicinal products based on genome editing must undergo rigorous preclinical testing and are subject to regulatory oversight for proper risk assessment prior to first evaluation in humans. We give a European perspective on the regulatory expectations to translate genome editing to the clinic to ensure their timely progress to market.
CITATION STYLE
Cathomen, T., Schüle, S., Schüßler-Lenz, M., & Abou-El-Enein, M. (2019, February 1). The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends in Biotechnology. Elsevier Ltd. https://doi.org/10.1016/j.tibtech.2018.06.005
Mendeley helps you to discover research relevant for your work.